Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
In order to test the hypotheses that pretreatment metabolic activity in the midbrain and the rostral anterior cingulate may predict remission in response to medications enhancing monoaminergic transmission, we compared relative regional cerebral metabolic rate of glucose (rCMRglu) using positron emission tomography (PET) in medication-free patients with major depression who remitted after 3 months of monoaminergic medication, with non-remitters on the same treatment. [18F]-FDG PET was conducted in a group of 33 drug-free DSM-IV major depression subjects prior to antidepressant treatment. Patients were prescribed paroxetine initially (61%) unless they had failed paroxetine previously. Treatment was then managed by the subjects’ own physician with 91% receiving a selective serotonin reuptake inhibitor and 78% another non-selective monoamine reuptake inhibitor during the 3 months of treatment. Voxel-based parametric brain maps of remitters were compared with maps of non-remitters using SPM2. Remission was defined as a N50% decrease in and a final score of ≤10 on the 24-item Hamilton Depression Rating Scale. We found that treatment remitters have lower activity in a single contiguous brain region (with global maxima in the midbrain, cluster level P=0.013, corrected for multiple comparison (CMC)), prior to treatment, compared with non-remitters to 3 months of community-based monoaminergic antidepressant treatment. Degree of improvement correlated with pretreatment midbrain activity. Pretreatment clinical picture and intensity of treatment did not distinguish remitters. No other area of the brain showed a significant difference between remitters and non-remitters even with CMC completely disabled. Lower relative regional brain activity in the region of monoaminergic nuclei prior to treatment predicts remission in response to 3 months of antidepressant treatment, despite no clinical differences at baseline and no difference in treatment intensity. Brain imaging is a potential objective laboratory technique that may guide treatment selection where clinical methods have not shown promise. Prospective studies are needed to replicate these findings and determine whether outcome prediction is limited to a specific class of antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 4×
“Rates of remission after antidepressant treatment, defined as both a 50% decline in HDRS and a final 17-item score of <7 or <10 for the 24 item HDRS (Frank et al., 1991), are even lower, only 20%–35% (Mann, 2005).”
BackgroundMethodInfluentialLimbic-cortical dysregulation: a proposed model of depression
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.3.471 · Cited by 1,585 · cited 5×
“It was first reported by Mayberg et al. (1997) that rCMRglu in the anterior cingulate may also be a predictor of favorable treatment response (not remission) by 60% of the studies.”
BackgroundMethodInfluentialThe Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230 · cited 2×
“Brain regions that may predict clinical response may be hypothesized based on the monoamine deficiency hypotheses of depression that posit diminished brain monoaminergic function (Achor, 1959; Kur’Ianova, 1959; Stein, 1961; Koutsky et al., 1962; Bunney and Davis, 1965; Coppen, 1967; Feer, 1967; Schildkraut, 1967; Copp…”
BackgroundMayberg, H. S., Brannan, S. K., Tekell, J. L., Silva, J. A., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01036-2 · Cited by 1,115
Cingulate function in depression: a potential predictor of treatment response
Mayberg, H. S., Brannan, S. K., Mahurin, R. K., Jerabek, P. A., Brickman, J. S., Tekell, J. L., Silva, J. A., McGinnis, S., Glass, T. G., Martin, C. C., et al. (1997) · NeuroReport · doi:10.1097/00001756-199703030-00048 · Cited by 1,029
Kennedy, S. H., Evans, K. R., Krüger, S., Mayberg, H. S., Meyer, J. H., McCann, S., Arifuzzman, A. I., Houle, S., & Vaccarino, F. J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.899 · Cited by 710 · cited 23×
“Thresholds were set a priori to P=0.01 and to P≤0.05 for height and extent thresholds respectively after correction for multiple comparisons by SPM2.”
BackgroundMethodInfluentialPet imaging of serotonin 1A receptor binding in depression
Drevets, W. C., Frank, E., Price, J. C., Kupfer, D. J., Holt, D., Greer, P. J., Huang, Y., Gautier, C., & Mathis, C. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00189-4 · Cited by 666 · cited 1×
“Several SPECT and PET scans using receptor-specific radioligands have found abnormal binding in the brainstem of depressed patients (Drevets et al., 1999, 2007; Morris et al., 1999; Dahlstrom et al., 2000; Willeit et al., 2000; Bhagwagar et al., 2004; Laasonen-Balk et al. 2004; Uusitalo et al.,…”
BackgroundBurden of Disease—Implications for Future Research
Michaud, C. M. (2001) · JAMA · doi:10.1001/jama.285.5.535 · Cited by 594 · cited 2×
“Major depressive disorder (MDD) is one of the leading causes of disability and burden of illness worldwide (Evans and Charney, 2003) and estimated to be second only to cardiovascular disease by 2020 (Michaud et al., 2001).”
BackgroundMeyer, J. H., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., Young, T., Praschak-Rieder, N., Wilson, A. A., & Houle, S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1209 · Cited by 585
Serotonin-1A receptor imaging in recurrent depression: replication and literature review
Drevets, W. C., Thase, M. E., Moses-Kolko, E. L., Price, J., Frank, E., Kupfer, D. J., & Mathis, C. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.06.008 · Cited by 399 · cited 1×
“Several SPECT and PET scans using receptor-specific radioligands have found abnormal binding in the brainstem of depressed patients (Drevets et al., 1999, 2007; Morris et al., 1999; Dahlstrom et al., 2000; Willeit et al., 2000; Bhagwagar et al., 2004; Laasonen-Balk et al. 2004; Uusitalo et al.,…”
Background
Cited by
Frontocingulate Dysfunction in Depression: Toward Biomarkers of Treatment Response
Pizzagalli, D. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.166 · Cited by 945
Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder
McGrath, C. L., Kelley, M. E., Holtzheimer, P. E., Dunlop, B. W., Craighead, W. E., Franco, A. R., Craddock, R. C., & Mayberg, H. S. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.143 · Cited by 561
Fu, C. H. Y., Steiner, H., & Costafreda, S. G. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.008 · Cited by 399
“…Frodl et al., 2011; Fu et al., 2008a, 2008b; Konarski et al., 2009; Langenecker et al., 2007; Little et al., 1996, 2005; Marquand et al., 2008; Milak et al., 2009; Ritchey et al., 2011; Roy et al., 2010; Samson et al., 2011; Saxena et al., 2003; Siegle et al., 2006; Wagner et al., 2010; Walsh…”
BackgroundDunlop, B. W., Rajendra, J. K., Craighead, W. E., Kelley, M. E., McGrath, C. L., Choi, K. S., Kinkead, B., Nemeroff, C. B., & Mayberg, H. S. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050518 · Cited by 342
“pre-treatment resting state metabolism in the midbrain did predict remission to standard antidepressant medications (69).”
Neuroimaging biomarkers as predictors of treatment outcome in Major Depressive Disorder
Fonseka, T. M., MacQueen, G. M., & Kennedy, S. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.049 · Cited by 185
Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder
Bunney, B. G., Li, J. Z., Walsh, D. M., Stein, R., Vawter, M. P., Cartagena, P., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Watson, S. J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.138 · Cited by 180
The role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment
Giménez-Palomo, A., Dodd, S., Anmella, G., Carvalho, A. F., Scaini, G., Quevedo, J., Pacchiarotti, I., Vieta, E., & Berk, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.546801 · Cited by 140
Neuroimaging-based biomarkers for treatment selection in major depressive disorder
Dunlop, B. W., & Mayberg, H. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/bdunlop · Cited by 127
“58 In the largest study to date, smaller left hippocampal volumes predicted poorer response among 167 depressed inpatients treated with medication; this effect was primarily driven by patients with recurrent MDD. Smaller hippocampal volume is also associated with poorer treatment outcomes…”
BackgroundBlood, A. J., Iosifescu, D. V., Makris, N., Perlis, R. H., Kennedy, D. N., Dougherty, D. D., Kim, B. W., Lee, M. J., Wu, S., Lee, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013945 · Cited by 126
“In humans with MDD, there has recently been detection of functional abnormalities in these subcortical regions [2,31,32], in addition to well-established abnormalities in target regions receiving subcortical projections [33,34,35,36,37,38,39,40,41,42,43,44,45,46,47].”
BackgroundLi, B., Zhang, S., Li, M., Hertz, L., & Peng, L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1631-3 · Cited by 52
Metadata
- Authors
- Milak, M. S., Parsey, R. V., Lee, L., Oquendo, M. A., Olvet, D. M., Eipper, F., Malone, K., & Mann, J. J.
- Venue
- Psychiatry Research: Neuroimaging
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 173
- Issue
- 1
- Pages
- 63-70
- ISSN
- 0925-4927 (ISSN-L)
- OpenAlex
- W2063122336
- Cited by
- 58
- References
- 15
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.